United States

People: Integra LifeSciences Holdings Corp (IART.O)

IART.O on Nasdaq

21 Oct 2016
Change (% chg)

$0.65 (+0.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Essig, Stuart 

Mr. Stuart M. Essig, Ph.D., is the Independent Chairman of the Board of Integra LifesSciences Holdings Corporation. He is Integra’s Chairman of the Board of Directors. He has been our Chairman since January 2012 and a director since he joined Integra in December 1997. He also served as our Chief Executive Officer from December 1997 until January 2012. In addition, he served as our President from December 1997 until November 2010. He currently serves as Managing Director of Prettybrook Partners LLC. Before joining Integra, Dr. Essig supervised the medical technology practice at Goldman, Sachs & Co. as a Managing Director. Dr. Essig had ten years of broad health care experience at Goldman Sachs serving as a senior merger and acquisitions advisor to a broad range of domestic and international medical technology, pharmaceutical and biotechnology clients. Dr. Essig has chaired Audit, Compensation and Nominating and Governance Committees and served on the boards of several NASDAQ and NYSE listed companies ranging in size from several hundred million dollars to $20 billion in market capitalization. Dr. Essig currently serves on the Board of Directors of St. Jude Medical Corporation and Owens & Minor, Inc. and as Chairman of the Board of Directors of Breg, Inc. He is a founding investor member of Tigerlabs, a Princeton-based business accelerator. He is an Executive in Residence at Cardinal Partners and a Venture Partner at Wellington Partners Advisory AG, both venture capital firms and serves as a Senior Advisor to TowerBrook Capital Partners. From March 2005 until August 2008, he served on the Board of Directors of Zimmer Holdings, Inc., and from 1998 to 2002 he served on the Board of Directors of Vital Signs, Inc. Dr. Essig Dr. Essig received an A.B. degree, magna cum laude, from the Woodrow Wilson School of Public and International Affairs at Princeton University and an M.B.A. and Ph.D. in Financial Economics from the University of Chicago, Graduate School of Business.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Awards, USD 214,070
Long-Term Incentive Plans, USD --
All Other, USD 1,577,220
Fiscal Year Total, USD 1,791,290

Options Compensation

  Quantity Market Value
Exercisable 209,042 4,934,190.00
Unexercisable 625,996 5,753,120.00
Exercised 282,086 8,798,260.00
Name Fiscal Year Total

Stuart Essig


Peter Arduini


Glenn Coleman


Lisa Evoli


Kenneth Burhop


John Mooradian

As Of  30 Dec 2015